Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119964 | 0.99 | ADORA1 (0.70) | ADORA1ADORA2AADORA3ADORA2BALOX15 | |
| SCHEMBL3745649 | 0.91 | ADORA3 (0.75) | ADORA1ADORA2AADORA3ADORA2BALOX15 | |
| SCHEMBL121441 | 0.86 | ADORA3 (0.69) | ADORA1ADORA2AADORA3ADORA2BMEN1 | |
| SCHEMBL118827 | 0.85 | ADORA3 (0.69) | ADORA1ADORA2AADORA3ADORA2BMEN1 | |
| SCHEMBL120576 | 0.85 | ADORA1 (0.64) | ADORA1ADORA2AADORA3ADORA2BALOX15 | |
| SCHEMBL14829529 | 0.82 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BALOX15 | |
| SCHEMBL29385091 | 0.82 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BALOX15 | |
| SCHEMBL1914129 | 0.82 | ADORA1 (1.00) | ADORA1ADORA2AADORA3ADORA2BALOX15 | |
| SCHEMBL20180024 | 0.78 | ADORA3 (0.72) | ADORA1ADORA2AADORA3ADORA2BALOX15 | |
| SCHEMBL9455871 | 0.77 | ADORA3 (0.55) | ADORA1ADORA2AADORA3ADORA2BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247715-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | Inotek Pharmaceuticals Corporation (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016090005-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2016-06-09 | — | — | WO | disclosed |
| EP-2968388-A1 | A METHOD OF PROVIDING OCULAR NEUROPROTECTION | Inotek Pharmaceuticals Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2424546-B1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORP (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014152733-A1 | A METHOD OF PROVIDING OCULAR NEUROPROTECTION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275128-A1 | METHOD OF PROVIDING OCULAR NEUROPROTECTION | INOTEK PHARMACEUTICALS CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130217643-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-08-22 | — | — | US | disclosed |
| US-8470800-B2 | Method of reducing intraocular pressure in humans | INOTEK PHARMACEUTICALS CORPORATION (US) | 2013-06-25 | — | — | US | disclosed |
| EP-2424546-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | Inotek Pharmaceuticals Corporation (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010127210-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100279970-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279970-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE6G, NDUFB7, PDE3A | ADORA1 1957/4885ADORA2A 2480/4885ADORA3 3673/4885 |
| US-20140275128-A1 | METHOD OF PROVIDING OCULAR NEUROPROTECTION | ALDH1A2, GAP43, ALDH1A3 | ADORA1 101/4885ADORA2A 24/4885ADORA3 226/4885 |
| US-20130217643-A1 | METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS | PDE6G, NDUFB7, PDE3A | ADORA1 1957/4885ADORA2A 2480/4885ADORA3 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.